Concepedia

Francisco Adrián

FA

Statistics

Publications

25

Citations

3K

H-Index

20

Active since

2000

Affiliations

Genomics Institute of the Novartis Research Foundation(Current)

Sanofi (France)

Dana-Farber Cancer Institute

Harvard University

Sanofi (United States)

Francisco Adrián is an author at Genomics Institute of the Novartis Research Foundation specializing in pharmacology, medicine, and drug discovery.

Publications per year

2000–2022

25

Publications

25

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

Jianming Zhang, Francisco Adrián, Wolfgang Jahnke et al. · Nature · 2010 · 599 citations

, , +14

<i>In silico</i> activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen

David Plouffe, Achim Brinker, Case W. McNamara et al. · Proceedings of the National Academy of Sciences · 2008 · 452 citations · Full text

, , +14

Allosteric inhibitors of Bcr-abl–dependent cell proliferation

Francisco Adrián, Qiang Ding, Taebo Sim et al. · Nature Chemical Biology · 2006 · 378 citations · Full text

, , +13

Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition

Michael Lampa, Heike Arlt, Timothy He et al. · PLoS ONE · 2017 · 168 citations · Full text

, , +17

A General Strategy for Creating “Inactive-Conformation” Abl Inhibitors

Okram Barun, A. S. Nagle, Francisco Adrián et al. · Chemistry & Biology · 2006 · 145 citations · Full text

, , +14

1–5 of 25